BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, Lawitz EJ, Kort J, Collins C. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses 2018;10:E462. [PMID: 30154359 DOI: 10.3390/v10090462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Randolph JT, Voight EA, Greszler SN, Uno BE, Newton JN, Gleason KM, Stolarik D, Van Handel C, Bow DAJ, DeGoey DA. Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). J Med Chem 2020;63:11034-44. [PMID: 32881503 DOI: 10.1021/acs.jmedchem.0c00956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML, Hassan MA, Pearlman BL, Hinestrosa F, Jacobson IM, Morelli G, Peter JA, Vainorius M, Michael LC, Fried MW, Wang GP, Lu W, Larsen L, Nelson DR. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology 2019;157:1506-1517.e1. [DOI: 10.1053/j.gastro.2019.08.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]